Business
QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published
AbbVie (NYSE: ABBV) announced today that the RAMQ has listed QULIPTA® in their formulary for the prevention of chronic migraine and episodic migraine.i This will be followed by reimbursement by private plans, mimicking the public formulary. The Institut national d'excellence en santé et en services sociaux (INESSS) previously published a positive recommendation for the public listing of QULIPTA® (atogepant) in the treatment of chronic migraine in adults on July 2, 2025.ii
About this update from Abbvie Inc.
[{"type":"text","content":"- Expanded access provides an additional treatment option for those with chronic migraine.- AbbVie is dedicated to people living with this debilitating disease and continues its commitment by providing multiple treatments and programs for these individuals.","length":258,"tagName":"p"},{"type":"text","content":"MONTREAL, Sept. 25, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that the RAMQ has listed QULIPTA® in their formulary for the prevention of chronic migraine and episodic migraine.i This will be followed by reimbursement by private plans, mimicking the public formulary. The Institut national d'excellence en santé et en services sociaux (INESSS) previously published a positive recommendation for the public listing of QULIPTA® (atogepant) in the treatment of chronic migraine in adults on July 2, 2025.ii ","length":518,"tagName":"p"},{"type":"image","alt":"AbbVie logo (CNW Group/AbbVie Canada)","displaySize":"","headline":null,"caption":"AbbVie logo (CNW Group/AbbVie Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":70,"url":"https://media.zenfs.com/en/cnwgroup.com/6dbf9b1cdd69f27d6b25b1d6a682ac51"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C7qtEkxBHC4OOvFtAwO6dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/6dbf9b1cdd69f27d6b25b1d6a682ac51","width":400,"height":70}},"href":"https://mma.prnewswire.com/media/2781472/AbbVie_Canada_QULIPTA_%C2%A0_atogepant__Now_Publicly_Reimbursed_in_Qu.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"INESSS has also finalized a class review of CGRP inhibitors in prevention that simplified access to newer treatments like QULIPTA®. Public reimbursement criteria have changed from requiring failure of 3 oral generic preventive medication classes (anti-hypertensive, anti-depressant & anti-epileptic) to only 2 failures.iii","length":326,"tagName":"p"},{"type":"text","content":"The public listing of QULIPTA® for both episodic and chronic migraine prevention, as well as the removal of a third failure on non-migraine-specific medications, is great news for Quebec patients living with migraine who will now have faster access to effective and well tolerated anti-CGRP preventive medications. These changes also better align with the updated Canadian Headache Socie...